SCHEMBL3603709

SCHEMBL3603709

CN(CCNC(=O)Cn1ncc2ccc(Br)cc21)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.43
TSHR P16473 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
WNT1 P04628 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
ALDH1A1 P00352 1/20 0.37
BCHE P06276 3/20 0.37
ACHE P22303 3/20 0.37
CCKAR P32238 1/20 0.37
CCKBR P32239 1/20 0.37
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602593 0.86 TSHR (0.57) TSHRL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3586854 0.86 KDM4E (0.42) KMOTSHRL3MBTL1NPC1RAB9A
SCHEMBL3591066 0.82 ALDH1A1 (0.46) TSHRSMN1; SMN2GAATP53MAPT
SCHEMBL3603706 0.81 KMO (0.46) KMOTSHRL3MBTL1NPC1RAB9A
SCHEMBL14365943 0.80 TP53 (0.48) TSHRL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3607948 0.77 KMT2A (0.39) TSHRNPC1RAB9ASMN1; SMN2GAA
SCHEMBL3585647 0.76 ATM (0.43) RAB9ASMN1; SMN2TP53MAPTMEN1
SCHEMBL3597424 0.76 TSHR (0.41) TSHRL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL13115698 0.75 GABRP (0.40) TSHRRAB9ASMN1; SMN2GAATP53
SCHEMBL3198668 0.74 ATM (0.49) TP53MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KMO 4469/4885TSHR 1277/4885L3MBTL1 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.